Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta Ltd. has announced a renounceable pro rata rights offer to its shareholders in Australia and New Zealand, allowing them to acquire new shares and attaching options. This offer leads to an adjustment in the exercise price of existing options, reflecting the company’s strategic move to raise capital and potentially enhance shareholder value.
More about AdAlta Ltd.
AdAlta Ltd. is a biotechnology company focused on developing innovative therapies using its proprietary i-body technology. The company operates primarily in the pharmaceutical industry, targeting unmet medical needs with a focus on novel biologic drugs.
Average Trading Volume: 801,102
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.22M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.